Company news: Eli Lilly and Boehringer Ingelheim

Share this article:
Eli Lilly will pay Boehringer Ingelheim $387.4 million as part of a deal to jointly develop and commercialize several diabetes pipeline agents. Products covered under the pact include two oral agents from BI—DPP-4 inhibitor linagliptin, filed with the FDA, and SGLT-2 inhibitor BI10773, in Phase III—and two basal insulin analogues from Lilly which will enter Phase III this year, plus an option on Lilly's anti-TGF-beta monoclonal antibody. The firms will split revenues from any approved drugs, and the deal includes milestone payments -- up to $1 million for Lilly and up to  $807 million for BI. “This deal should inject some life into [Lilly's] diabetes franchise, which has been losing share,” wrote Credit-Suisse analyst Catherine Arnold in an investor note today.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.